NIAID

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.
July 14, 2020

VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

By Leigh MacMillan
July 13, 2020

“Nur” target may aid arthritis treatment

Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.

By Bill Snyder
July 9, 2020

Recurrent UTIs linked to hidden reservoir

Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.

By Sarah E. Glass
June 10, 2020

C. diff captures blood cell cofactor to build defensive shield

Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.

By Leigh MacMillan
Jim Cassat, MD, PhD, and colleagues are studying enzymes involved in metabolism that are particularly important for Staphylococcus aureus to survive in host tissues.
June 3, 2020

Study explores how staph bacteria can survive in bone

A comprehensive evaluation of the metabolic pathways that support Staphylococcus aureus (“staph”) growth during invasive bone infections could offer new targets for treatment.

By Leigh MacMillan
May 14, 2020

Antibodies eye Pacific Island “fever”

Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

By Bill Snyder
May 14, 2020

The adaptable anthrax bacterium

Vanderbilt researchers discover how anthrax bacterium defends itself against structural damage and resists the toxicity of the antimicrobial drug targocil.
By Leigh MacMillan
May 12, 2020

Study to determine rate of novel coronavirus infection in U.S. children

Researchers at Vanderbilt University Medical Center (VUMC) are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families.
By Kelsey Herbers
April 30, 2020

Antibody finding raises hopes for Marburg, COVID-19 treatments

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.
By Bill Snyder
February 6, 2020

Powering H. pylori pathogenesis

Timothy Cover and colleagues report new insights into the sources of energy used by a bacterial “machine” linked to the pathogenesis of stomach cancer.
By Leigh MacMillan
February 5, 2020

Vaccine Program receives NIH renewal of VTEU

The Vanderbilt Vaccine Research Program has received a grant from the NIH to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units.
By Bill Snyder
January 13, 2020

Zinc uptake by a deadly pathogen

The increasingly antibiotic-resistant bacterium Acinetobacter baumannii requires zinc to cause infection, and Vanderbilt researchers have identified the zinc uptake system it uses.
By Leigh MacMillan
January 10, 2020

Structural views of a C. diff toxin

D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics.
By Leigh MacMillan
1 … 3 4 5 6 7 … 15